Since the serendipitous discovery of the first class of modern antidepressants in the 1950's, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widespread availability of antidepressants, as many as 50% of depressed patients are resistant to these conventional therapies. The significant length of time required to produce meaningful symptom relief with these medications, 4-6 weeks, indicates that other mechanisms are likely involved in the pathophysiology of depression which may yield more viable targets for drug development. For decades, no viable candidate target with a different mechanism of action to that of conventional therapies proved successful in clinical studies. Now several exciting avenues for drug development are under intense investigation. One of these emerging targets is modulation of endogenous opioid tone. This review will evaluate preclinical and clinical evidence pertaining to opioid dysregulation in depression, focusing on the role of the endogenous ligands endorphin, enkephalin, dynorphin, and nociceptin/orphanin FQ (N/OFQ) and their respective receptors, mu (MOR), delta (DOR), kappa (KOR), and the N/OFQ receptor (NOP) in mediating behaviors relevant to depression and anxiety. Finally, putative opioid based antidepressants that are under investigation in clinical trials, ALKS5461, JNJ-67953964 (formerly LY2456302 and CERC-501) and BTRX-246040 (formerly LY-2940094) will be discussed. This review will illustrate the potential therapeutic value of targeting opioid dysregulation in developing novel therapies for MDD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859062 | PMC |
| http://dx.doi.org/10.1016/j.pharmthera.2019.04.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paroxysmal sympathetic hyperactivity: A common consequence of traumatic brain injury.
Auton Neurosci
January 2025
Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan. Electronic address:
Paroxysmal Sympathetic Hyperactivity (PSH) is a challenging and often underrecognized syndrome, commonly arising after a traumatic brain injury (TBI). Characterized by episodic bursts of heightened sympathetic activity, PSH presents with a distinct constellation of symptoms including hypertension, tachycardia, hyperthermia, and diaphoresis. While the exact pathophysiology remains elusive, current evidence suggests that the syndrome results from an imbalance between excitatory and inhibitory neuronal pathways within the central nervous system, leading to dysregulated autonomic responses.
View Article and Find Full Text PDFMachine learning analysis of the orbitofrontal cortex transcriptome of human opioid users identifies Shisa7 as a translational target relevant for heroin-seeking leveraging a male rat model.
Biol Psychiatry
December 2024
Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Addiction Institute of Mount Sinai, New York, New York, USA. Electronic address:
Background: Identifying neurobiological targets predictive of the molecular neuropathophysiological signature of human opioid use disorder (OUD) could expedite new treatments. OUD is characterized by dysregulated cognition and goal-directed behavior mediated by the orbitofrontal cortex (OFC), and next-generation sequencing could provide insights regarding novel targets.
Methods: Here, we used machine learning to evaluate human post-mortem OFC RNA-sequencing datasets from heroin-users and controls to identify transcripts predictive of heroin use.
Multi-omic network analysis identifies dysregulated neurobiological pathways in opioid addiction.
Biol Psychiatry
November 2024
Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN. Electronic address:
Background: Opioid addiction is a worldwide public health crisis. In the United States, for example, opioids cause more drug overdose deaths than any other substance. Yet, opioid addiction treatments have limited efficacy, meaning that additional treatments are needed.
View Article and Find Full Text PDFTransdiagnostic features of inflammatory markers and executive function across psychiatric disorders.
J Psychiatr Res
November 2024
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; YiNing Hospital, Beijing, China.
Executive dysfunction and dysregulated inflammation are found in patients with different psychiatric disorders. However, whether there are different associations between inflammatory markers and executive performance in patients with different psychiatric diagnoses is unknown. Our study aims were (1) to compare peripheral cytokine expression and executive function in patients with bipolar disorder (BD), substance use disorder (SUD), and schizophrenia (SCZ), and in healthy controls (HC) and (2) to explore the potential association between inflammatory cytokines and executive function in different patient groups and HC.
View Article and Find Full Text PDFTransdiagnostic factors predicting prescription opioid-use disorder severity: A 12-month prospective study in patients on long-term opioid therapy for chronic pain.
Drug Alcohol Depend
January 2025
Center for Applied Psychology, Miguel Hernández University, Avenida Universidad, s/n, Elche 03202, Spain. Electronic address:
Article Synopsis
- Research indicates that certain psychological factors, such as anticipatory pleasure and cognitive control, significantly impact the severity of Prescription Opioid-Use Disorder (POUD) in chronic pain patients on long-term opioid therapy.
- A study involving 67 patients revealed that the inability to experience pleasure, poor emotional regulation, and sleep quality were strong predictors of increased POUD severity over time.
- The findings suggest that targeting these psychological factors could help in identifying patients at risk and improving treatment strategies for those dealing with chronic pain and opioid use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!